DOTS Trial Insights: Evaluating an Antibiotic's Role in Complicated Staphylococcus aureus Bacteremia
The DOTS trial results found that although dalbavancin did not demonstrate superiority over standard intravenous therapy for complicated Staphylococcus aureus bacteremia, it was noninferior in efficacy, with similar safety, and offers a convenient 2-dose alternative that may reduce OPAT-related complications and health care utilization in select patients.
Advertisement
Advertisement
Trending on Contagion Live
1
FDA Says US Food Supply Safe as Cyclosporiasis Cases Top 11,000
2
H5N1: Have We Forgotten About Avian Influenza?
3
Ensitrelvir Becomes First Oral Option Available in US to Prevent COVID-19
4
Sharon Nachman, MD, on How Pediatric AMR Forecasts Should Change Prescribing
5